RECURRENT INTRAHEPATIC CHOLANGIOCARCINOMA
Clinical trials for RECURRENT INTRAHEPATIC CHOLANGIOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT INTRAHEPATIC CHOLANGIOCARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT INTRAHEPATIC CHOLANGIOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for tough bile duct cancers
Disease control OngoingThis study tests whether adding the targeted drug binimetinib to standard chemotherapy (FOLFOX) can shrink tumors or help people with advanced bile duct or gallbladder cancer live longer. About 66 adults whose cancer has a specific genetic change (MAPK pathway mutation) and has w…
Matched conditions: RECURRENT INTRAHEPATIC CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 03:15 UTC
-
New drug combo targets tough cancers: hope for liver, pancreas, and bile duct tumors
Disease control OngoingThis early-phase study tests a combination of two drugs, guadecitabine and durvalumab, in people with advanced liver, pancreatic, bile duct, or gallbladder cancer that has spread. The main goals are to find the safest dose and see if the drugs can shrink tumors. About 55 particip…
Matched conditions: RECURRENT INTRAHEPATIC CHOLANGIOCARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated May 12, 2026 13:42 UTC